Last reviewed · How we verify
NCT05210881
Weaning From Nasal High Flow Therapy
trial in Respiratory Distress Syndrome, Adult in 62 participants. Completed in 31 August 2021.
31 December 2019
Quick facts
| Lead sponsor | Hôpital Louis Mourier |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 62 |
| Start date | 1 January 2019 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 August 2021 |
| Sites | 1 location across France |
Conditions studied
- Respiratory Distress Syndrome, Adult — all drugs for Respiratory Distress Syndrome, Adult →
- Acute Hypoxemic Respiratory Failure — all drugs for Acute Hypoxemic Respiratory Failure →
- Acute Respiratory Distress Syndrome — all drugs for Acute Respiratory Distress Syndrome →
- Weaning Failure — all drugs for Weaning Failure →
Sponsor
Hôpital Louis Mourier
Who can join
18 and older, any sex, with Respiratory Distress Syndrome, Adult or Acute Hypoxemic Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Nasal high flow is widely used in critically ill patients admitted to the intensive care unit (ICU) for acute hypoxemic respiratory failure. It has been shown to improve patient comfort, increase oxygenation and reduce need for intubation in some patients. The Respiratory Oxygenation (ROX) index has been established as a simple tool to help clinicians identify those patients who will succeed and those who will fail under nasal high flow and therefore predict the need for intubation. However, when nasal high flow therapy is successful, little is known as to how and when weaning of this device should be performed and what are the predictors of a safe withdrawal of the device. The objectives of this retrospective exploratory study are to identify a cut-off value of the ROX index predictive of success of the withdrawal trial, to describe a one-year use of the withdrawal trial; to describe the ROX value closest to weaning from nasal high flow, and to identify factors associated with success or failure of the withdrawal trial from nasal high flow therapy in patients receiving nasal high flow therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05210881
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Respiratory Distress Syndrome, Adult
Currently open trials in the same condition.
- NCT06203405 — The Efficacy of P0.1-guided Sedation Protocol in Critically Ill Patients Receiving Invasive Mechanical Ventilation: A Ra · NA · recruiting
- NCT04545424 — Trial of Therapeutic Hypothermia in Patients With ARDS · Phase 2 · recruiting
- NCT03368092 — Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma · Phase 3 · recruiting
- NCT03709199 — Long Term Follow up of Children Enrolled in the REDvent Study · active not recruiting
Other Hôpital Louis Mourier trials
Trials by the same sponsor.
- NCT05124197 — Extended Prone Position Duration COVID-19-related ARDS: a Retrospective Study · completed
- NCT04385823 — Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure · completed
- NCT03290105 — Microbial and Pharmacological Assessment of Chlorhexidine · completed
- NCT03303937 — Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05210881 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hôpital Louis Mourier
- Last refreshed: 27 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05210881.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing